Researchers presented the largest pooled MRD dataset in acute myeloid leukemia (AML) showing that minimal residual disease (MRD) negativity prior to consolidation correlates with longer overall survival, and could serve as an intermediate endpoint to expedite drug approvals. Jesse Tettero (Fralin Biomedical Research Institute) led the analysis presented at ASH. MRD testing here used multiparameter flow cytometry to detect residual leukemic cells. MRD (minimal residual disease) refers to low levels of cancer cells remaining after treatment. Regulators have accepted MRD as a surrogate in some hematologic cancers before, and these data are positioned to influence AML trial design and accelerated approval pathways.